Iterum Therapeutics Plc (ITRM)

Jan 01, 2025

Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Drops By 10.3% - Defense World

Jan 01, 2025

Dec 07, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Eastern Progress Online

Dec 07, 2024

Dec 02, 2024

Iterum Therapeutics stock hits 52-week high at $2.35 By Investing.com - Investing.com UK

Dec 02, 2024

Nov 23, 2024

Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register

Nov 23, 2024

Nov 21, 2024

Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times

Nov 21, 2024

Nov 19, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA - GuruFocus.com

Nov 19, 2024

Nov 15, 2024

Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

Nov 15, 2024

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

Iterum Therapeutics plc (ITRM) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... By GuruFocus - Investing.com Canada

Nov 15, 2024

Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval - TipRanks

Nov 14, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Iterum Therapeutics PLC - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.24 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

Iterum Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 14, 2024

Nov 14, 2024

Iterum Therapeutics sees cash runway into 2025 - TipRanks

Nov 14, 2024

Nov 14, 2024

Iterum's ORLYNVAH Gets FDA Nod; Q3 Shows $14.5M Cash Position Amid Wider Losses | ITRM Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Iterum Therapeutics (ITRM) Scheduled to Post Earnings on Thursday - Defense World

Nov 13, 2024

Nov 13, 2024

A Look at Iterum Therapeutics's Upcoming Earnings Report - Benzinga

Nov 13, 2024

Nov 11, 2024

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - The Manila Times

Nov 11, 2024

Nov 02, 2024

Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India

Nov 02, 2024

Nov 01, 2024

Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia

Nov 01, 2024

Nov 01, 2024

Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com

Nov 01, 2024

Nov 01, 2024

500: Something went wrong - Investing.com UK

Nov 01, 2024

Oct 29, 2024

ITRMIterum Therapeutics plc Ordinary Share Latest Stock News & Market Updates - StockTitan

Oct 29, 2024

Oct 29, 2024

FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections - Contagionlive.com

Oct 29, 2024

Oct 28, 2024

Iterum Scores First Approval For Oral Penem Antibiotic - News & Insights

Oct 28, 2024

Oct 28, 2024

Second Oral UTI Treatment Approved, But Still No Vaccine - Precision Vaccinations

Oct 28, 2024

Oct 28, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Oct 28, 2024

Oct 28, 2024

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Benzinga

Oct 28, 2024

Oct 28, 2024

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology

Oct 28, 2024

Oct 28, 2024

NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024 - Lelezard

Oct 28, 2024

Oct 26, 2024

Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs - MSN

Oct 26, 2024

Oct 26, 2024

Major Improvements In Iterum Therapeutics Plc (ITRM) Stock Need To Be Considered - Stocks Register

Oct 26, 2024

Oct 26, 2024

Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal

Oct 26, 2024

Oct 26, 2024

FDA approves new oral antibiotic ORLYNVAH for uUTIs By Investing.com - Investing.com Nigeria

Oct 26, 2024

Oct 25, 2024

Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com

Oct 25, 2024

Oct 25, 2024

Wall Street-Heavily Traded - WDRB

Oct 25, 2024

Oct 25, 2024

Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval - Marketscreener.com

Oct 25, 2024

Oct 25, 2024

FDA approves new oral antibiotic ORLYNVAH for uUTIs - Investing.com India

Oct 25, 2024

Oct 25, 2024

Iterum Therapeutics Gains FDA Approval for ORLYNVAH - TipRanks

Oct 25, 2024

Oct 25, 2024

US FDA approves Iterum's treatment for urinary infection - Reuters.com

Oct 25, 2024

Oct 25, 2024

Iterum Therapeutics announces FDA approval of Orlynvah - TipRanks

Oct 25, 2024

Oct 25, 2024

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Manila Times

Oct 25, 2024

Oct 20, 2024

Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM? - RTTNews

Oct 20, 2024